Trials of low‐dose anticoagulation,4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors,5 as well as statins2, 6 in patients with HF have been disappointing to date, and guideline recommendations for statins among patients with HF remain weak.3 This evidence concerns the gene PCSK9 and hydrops fetalis.